Branched and multi-chain nucleic acid switches for sensing and screening

• US 7,521,546 B2
• Filed: 08/02/2005
• Issued: 04/21/2009
• Est. Priority Date: 08/03/2004
• Status: Active Grant

• Current Assignee: Syracuse University
• Original Assignee: Syracuse University
• Inventors: Hudson, Bruce S., Borer, Philip N.
• Primary Examiner(s): Horlick; Kenneth R.
• Assistant Examiner(s): Baughman; Molly E
• Application Number:
  US11/195,547
• Publication Number:
  US 20060029933A1
• Time in Patent Office: 1,358 Days
• Field of Search: None
• US Class Current: 536/22.1
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2310/3517 Marker; Tag
• CPC Class Codes: C12Q 1/6818 involving interaction of two or more labels, e.g. resonant energy transfer
• CPC Class Codes: C12Q 1/70 involving virus or bacteriophage immunoassay for viruses G01N33/56983
• CPC Class Codes: C12Q 1/701 Specific hybridization probes
• CPC Class Codes: C12Q 2525/205 Aptamer
• CPC Class Codes: C12Q 2525/301 Hairpin oligonucleotides
• CPC Class Codes: C12Q 2525/313 Branched oligonucleotides
• CPC Class Codes: C12Q 2541/101 Selex
• CPC Class Codes: C12Q 2565/301 Pyrophosphate (PPi)
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Embodiments of the invention relate to a branched or multichain nucleic acid switch adapted to switch from a first conformation to a second conformation upon ligand binding. The switch includes a probe strand, P, which includes the ligand binding domain; a switching framework which includes a cover strand (C), and a tether that holds P and C together and a signaling apparatus. Some embodiments include a toggle strand (T) where now the tether holds P, C, T, and the signaling apparatus together. As the switch changes between the first and second conformations; the signaling apparatus reports the state of the switch. The signaling entity is typically a lumiphore and a quencher located along the switching framework. Nucleic acid switches have applications in real time assays for diverse agents including infectious agents, environmental toxins, and terrorist agents, as well as screening methods for such agents. Further applications are found for nanoelectronics, nanofabrication and nanomachines.

Claims

1. A branched or multichain nucleic acid switch adapted to switch from a first conformation to a second conformation upon ligand binding, said switch comprising:

a probe strand P comprising a ligand binding domain;

a switching framework comprising a cover strand (C), which is partially but not completely complementary to P;

a tether that holds P and C together while the switch changes between the first and second conformations without dissociating the branched or multichain nucleic acid thereby creating a rapidly reversible switch;

a toggle strand (T) tethered to the P-strand and the C-strand by covalent linkage; and

a signaling apparatus comprising a combination of signaling entities, wherein a ligand for the ligand binding domain is selected from the group consisting of proteins, cell-surface features, and small molecules, and wherein the ligand binding domain is sequestered in the first conformation.

3. The branched or multichain nucleic acid switch of claim 1 or 2,wherein the probe strand is selected from the group consisting of DNA, RNA, modified nucleic acid, and combinations thereof.

4. The branched or multichain switch of claim 1 or 2, wherein said first conformation has P extensively hybridized to C and said second conformation has P not hybridized to C.

5. The branched or multichain switch of claim 1 or 2, wherein the signaling entities comprise a lumiphore and a quencher located along the switching framework.

6. The branched or multichain switch of claim 1 or 2, wherein the ligand binding domain comprises a naturally occurring RNA binding site or analog thereof or a naturally occurring DNA binding site or analog thereof or a combinatorially derived sequence or related fragment.

7. The branched or multichain switch of claim 1 or 2, wherein the ligand binding domain is adapted to bind a ligand which is selected from the group consisting of:

a disease agent, wherein the disease is Hepatitis C, Congo-Crimean hemorrhagic fever, Ebola hemorrhagic fever, Herpes, human cytomegalovirus, human pappiloma virus, influenza, Marburg, Q fever, Rift valley fever, Smallpox, Venezuelan equine encephalitis, HTV-1, MMTV, HIV-2, HTLV-1, SNY, BJV, BLV, EIAV, FIV, MMPV, Mo-MLV, Mo-MSV, M-PMV, RSV, SW, or AMV;

a retroviral component which is TAR-tat, RLRE-rev, DIS, PBS, RT, PR, IN, SU, TM, vpu, vif, vpr, nef, mos, tax, rex, sag, v-src, v-myc and precursors and protease products of the precursors, gag, gag-pol, env, src, or onc;

a toxin or other factor derived from bacteria or other microorganisms which are B. antliracis, Burkholderia pseudomallei, Botulinum, Brucellosis, Candida albicans, Cholera, Clostridium perfringins, Kinetoplasts, Malaria, Mycobacteria, Plague, Pneumocystis, Schistosomal parasites, Cryptosporidium, Giardia, Ricin, Saxitoxin, Shiga Toxin, Staphylococcus (including enterotoxin B), Trichothecene mycotoxins, Tularemia, or agents causing Toxoplasmosis; and

nerve gas agents, chemical poisons, contaminants of water supplies, contaminants of food and beverages, or contaminants of air.

8. A population of branched or multichain switch molecules according to claim 1 or 2, wherein there are more molecules with C hybridized to P, C:

P, than with P not hybridized to C,C_P, wherein the ratio of [C;

P/C_P] is from 10;

1 to 100;

1.

9. A population of branched or multichain switch molecules according to claim 1, wherein there are more molecules with C hybridized to P, C:

P, than with T hybridized to C, T;

C, wherein the ratio of[C;

P/T;

C] is from 10;

1 to 100;

1.

10. The branched or multichain switch of claim 1, wherein P, C and T are joined together at a vertex.

12. A kit comprising the branched or multichain switch of claim 1 for real time detection of a selected ligand.

2. A branched or multichain nucleic acid switch adapted to switch from a first conformation to a second conformation upon ligand binding, said switch comprising:

a probe strand P comprising a ligand binding domain;

a switching framework comprising a cover strand (C), which is partially but not completely complementary to P;

a tether that holds P and C together while the switch changes between the first and second conformations without dissociating the branched or multichain nucleic acid thereby creating a rapidly reversible switch; and

a signaling apparatus comprising a combination of signaling entities, wherein a ligand for the ligand binding domain is selected from the group consisting of proteins, cell-surface features, and small molecules, and wherein the ligand binding domain is sequestered in the first conformation,

wherein tethering occurs via a fastener duplex, F, to couple two covalently linked nucleic acid strands together by a non-covalent interaction, wherein the first strand comprises C and the second strand comprises P when the branched or multichain switch is in the second conformation.

11. A kit comprising the branched or multichain switch of claim 2 for real time detection of a selected ligand.

13. The branched multichain nucleic acid switch of claim 2, wherein the fastener duplex is a base-pair stem that does not vary between the first and second conformations of said switch.

14. A branched or multichain switch adapted to switch from a first conformation to a second conformation upon ligand binding, said switch comprising:

a first strand comprising a ligand binding domain;

a second strand; and

a fastener to couple the two strands together without dissociating the branched or multichain switch, thereby creating a rapidly reversible switch;

wherein the first strand and second strand hybridize to each other in the first conformation which sequesters the ligand binding domain and the ligand binding domain is free in the second conformation, wherein a ligand for the ligand binding domain is selected from the group consisting of proteins, cell-surface features, and small molecules.